Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
NCT03422029
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
177Lu-Dotatate PRRT
Sponsor
Peking University